Norges Bank’s Quince Therapeutics QNCX Stock Holding History

Norges Bank’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-50	Closed	-$463K	–	2157
2020 Q2	$463K	Buy	+50	New	+$458K	﹤0.01%	2052

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's QNCX Position: Q3 2020 in Review

Norges Bank sold out of Quince Therapeutics (QNCX) in Q3 2020, closing a stake of 50 shares — an estimated $463K sold.

Norges Bank first reported a position in QNCX in Q2 2020 and held it in 1 quarter. The position peaked at $463K in Q2 2020. 79 funds tracked by Wall St. Rank hold QNCX as of Q3 2020.

Norges Bank reported no remaining Quince Therapeutics position as of Q3 2020 after selling out during the quarter.
Norges Bank sold 50 Quince Therapeutics shares in Q3 2020, an estimated $463K.
Norges Bank first reported a position in Quince Therapeutics in Q2 2020 and held it in 1 quarter.
Norges Bank's Quince Therapeutics position peaked at $463K in Q2 2020.
79 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2020.

Based on Norges Bank's 13F filing for Q3 2020, filed 10 Nov 2020.